Journal Article
. 2019 Sep;394(10204).
doi: 10.1016/S0140-6736(19)31709-X.

Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence

Collaborative Group on Hormonal Factors in Breast Cancer  
  • PMID: 31474332
  •     23 citations

Abstract

Background: Published findings on breast cancer risk associated with different types of menopausal hormone therapy (MHT) are inconsistent, with limited information on long-term effects. We bring together the epidemiological evidence, published and unpublished, on these associations, and review the relevant randomised evidence.

Methods: Principal analyses used individual participant data from all eligible prospective studies that had sought information on the type and timing of MHT use; the main analyses are of individuals with complete information on this. Studies were identified by searching many formal and informal sources regularly from Jan 1, 1992, to Jan 1, 2018. Current users were included up to 5 years (mean 1·4 years) after last-reported MHT use. Logistic regression yielded adjusted risk ratios (RRs) comparing particular groups of MHT users versus never users.

Findings: During prospective follow-up, 108 647 postmenopausal women developed breast cancer at mean age 65 years (SD 7); 55 575 (51%) had used MHT. Among women with complete information, mean MHT duration was 10 years (SD 6) in current users and 7 years (SD 6) in past users, and mean age was 50 years (SD 5) at menopause and 50 years (SD 6) at starting MHT. Every MHT type, except vaginal oestrogens, was associated with excess breast cancer risks, which increased steadily with duration of use and were greater for oestrogen-progestagen than oestrogen-only preparations. Among current users, these excess risks were definite even during years 1-4 (oestrogen-progestagen RR 1·60, 95% CI 1·52-1·69; oestrogen-only RR 1·17, 1·10-1·26), and were twice as great during years 5-14 (oestrogen-progestagen RR 2·08, 2·02-2·15; oestrogen-only RR 1·33, 1·28-1·37). The oestrogen-progestagen risks during years 5-14 were greater with daily than with less frequent progestagen use (RR 2·30, 2·21-2·40 vs 1·93, 1·84-2·01; heterogeneity p<0·0001). For a given preparation, the RRs during years 5-14 of current use were much greater for oestrogen-receptor-positive tumours than for oestrogen-receptor-negative tumours, were similar for women starting MHT at ages 40-44, 45-49, 50-54, and 55-59 years, and were attenuated by starting after age 60 years or by adiposity (with little risk from oestrogen-only MHT in women who were obese). After ceasing MHT, some excess risk persisted for more than 10 years; its magnitude depended on the duration of previous use, with little excess following less than 1 year of MHT use.

Interpretation: If these associations are largely causal, then for women of average weight in developed countries, 5 years of MHT, starting at age 50 years, would increase breast cancer incidence at ages 50-69 years by about one in every 50 users of oestrogen plus daily progestagen preparations; one in every 70 users of oestrogen plus intermittent progestagen preparations; and one in every 200 users of oestrogen-only preparations. The corresponding excesses from 10 years of MHT would be about twice as great.

Funding: Cancer Research UK and the Medical Research Council.

The dangers of compounded bioidentical hormone replacement therapy.
Louise Newson, Janice Rymer.
Br J Gen Pract, 2019 Nov 02; 69(688). PMID: 31672802    Free PMC article.
Genistein as Potential Therapeutic Candidate for Menopausal Symptoms and Other Related Diseases.
Prakash Thangavel, Abraham Puga-Olguín, Juan F Rodríguez-Landa, Rossana C Zepeda.
Molecules, 2019 Nov 02; 24(21). PMID: 31671813    Free PMC article.
Review.
Can postfertile life stages evolve as an anticancer mechanism?
Frédéric Thomas, Mathieu Giraudeau, +6 authors, Alexandra Alvergne.
PLoS Biol, 2019 Dec 06; 17(12). PMID: 31805037    Free PMC article.
Update on Menopausal Hormone Therapy for Fracture Prevention.
Jan J Stepan, Hana Hruskova, Miloslav Kverka.
Curr Osteoporos Rep, 2019 Nov 20; 17(6). PMID: 31741221    Free PMC article.
Review.
"Bridging the Gap" Everything that Could Have Been Avoided If We Had Applied Gender Medicine, Pharmacogenetics and Personalized Medicine in the Gender-Omics and Sex-Omics Era.
Donato Gemmati, Katia Varani, +7 authors, Tiziana Bellini.
Int J Mol Sci, 2020 Jan 08; 21(1). PMID: 31906252    Free PMC article.
Review.
Prognostic Impact of Menopausal Hormone Therapy in Breast Cancer Differs According to Tumor Characteristics and Treatment.
Christopher Godina, Erik Ottander, +3 authors, Helena Jernström.
Front Oncol, 2020 Mar 03; 10. PMID: 32117735    Free PMC article.
A phase 2b, randomized, placebo-controlled, double-blind, dose-ranging study of the neurokinin 3 receptor antagonist fezolinetant for vasomotor symptoms associated with menopause.
Graeme L Fraser, Samuel Lederman, +5 authors, Steven Ramael.
Menopause, 2020 Feb 27; 27(4). PMID: 32102086    Free PMC article.
"I'm going to stay young":  Belief in anti-aging efficacy of menopausal hormone therapy drives prolonged use despite medical risks.
Mary M Hunter, Alison J Huang, Margaret I Wallhagen.
PLoS One, 2020 May 30; 15(5). PMID: 32469976    Free PMC article.
Exploring the effects of lifestyle on breast cancer risk, age at diagnosis, and survival: the EBBA-Life study.
Trygve Lofterød, Hanne Frydenberg, +7 authors, Inger Thune.
Breast Cancer Res Treat, 2020 May 22; 182(1). PMID: 32436147    Free PMC article.
Geographic Inequalities in Breast Cancer in Italy: Trend Analysis of Mortality and Risk Factors.
Paolo Giorgi Rossi, Olivera Djuric, +4 authors, Alessio Petrelli.
Int J Environ Res Public Health, 2020 Jun 18; 17(11). PMID: 32545263    Free PMC article.
Herbal Medicines (Danggui Liuhuang Decoctions) for Management of Menopausal Symptoms: A Systematic Review of Randomized Controlled Trials.
Ji Hee Jun, Hye Won Lee, +2 authors, Myeong Soo Lee.
J Clin Med, 2020 Jun 12; 9(6). PMID: 32521682    Free PMC article.
Review.
Association of Menopausal Hormone Therapy With Breast Cancer Incidence and Mortality During Long-term Follow-up of the Women's Health Initiative Randomized Clinical Trials.
Rowan T Chlebowski, Garnet L Anderson, +14 authors, Ross L Prentice.
JAMA, 2020 Jul 29; 324(4). PMID: 32721007    Free PMC article.
Influence of breast cancer risk factors and intramammary biotransformation on estrogen homeostasis in the human breast.
Daniela Pemp, Leo N Geppert, +6 authors, Leane Lehmann.
Arch Toxicol, 2020 Jun 24; 94(9). PMID: 32572548    Free PMC article.
Commentary: No multiplicative GXE interactions for breast cancer risk: Have we reached a verdict or is the jury still out?
Mary Beth Terry.
Int J Epidemiol, 2020 Jan 01; 49(1). PMID: 31891385    Free PMC article.
APOBEC3B expression in breast cancer cell lines and tumors depends on the estrogen receptor status.
Krizia-Ivana Udquim, Clara Zettelmeyer, +2 authors, Ludmila Prokunina-Olsson.
Carcinogenesis, 2020 Jan 14; 41(8). PMID: 31930332    Free PMC article.
Personalized early detection and prevention of breast cancer: ENVISION consensus statement.
Nora Pashayan, Antonis C Antoniou, +31 authors, Martin Widschwendter.
Nat Rev Clin Oncol, 2020 Jun 20; 17(11). PMID: 32555420    Free PMC article.
Review.
Uncovering New Drug Properties in Target-Based Drug-Drug Similarity Networks.
Lucreţia Udrescu, Paul Bogdan, +4 authors, Mihai Udrescu.
Pharmaceutics, 2020 Sep 20; 12(9). PMID: 32947845    Free PMC article.
Survey of Principal Investigators in Biobanking: Knowledge, Attitudes, and Research Behaviors About Transgender and Gender-Diverse Patients.
Nat C Jones, Monica E Reyes, Gwendolyn P Quinn, Matthew B Schabath.
JCO Oncol Pract, 2020 Jun 12; 16(10). PMID: 32525751    Free PMC article.
Use of hormone replacement therapy and risk of breast cancer: nested case-control studies using the QResearch and CPRD databases.
Yana Vinogradova, Carol Coupland, Julia Hippisley-Cox.
BMJ, 2020 Oct 30; 371. PMID: 33115755    Free PMC article.
Breast cancers, mammary stem cells, and cancer stem cells, characteristics, and hypotheses.
Sebastien Taurin, Haifa Alkhalifa.
Neoplasia, 2020 Nov 04; 22(12). PMID: 33142233    Free PMC article.
Review.
Open-label placebos for menopausal hot flushes: a randomized controlled trial.
Yiqi Pan, Ramona Meister, +3 authors, Yvonne Nestoriuc.
Sci Rep, 2020 Nov 20; 10(1). PMID: 33208855    Free PMC article.
Influence of Fermented Red Clover Extract on Skeletal Muscle in Early Postmenopausal Women: A Double-Blinded Cross-Over Study.
Mikkel Oxfeldt, Line Barner Dalgaard, +2 authors, Mette Hansen.
Nutrients, 2020 Nov 27; 12(11). PMID: 33238442    Free PMC article.
Use of postmenopausal hormone therapies and risk of histology- and hormone receptor-defined breast cancer: results from a 15-year prospective analysis of NIH-AARP cohort.
Shao-Ming Wang, Ruth M Pfeiffer, Gretchen L Gierach, Roni T Falk.
Breast Cancer Res, 2020 Nov 27; 22(1). PMID: 33239054    Free PMC article.